Related Experiment Videos
When prostate brachytherapy fails: a case report and discussion.
Cigall Kadoch1, Anthony V D'Amico, Richard H Matthews
1University of California, Berkeley, California, USA.
The Oncologist
|November 30, 2005
Summary
Prostate-specific antigen failure after brachytherapy is rare. For patients experiencing biochemical failure, a combination of hormonal therapy and pelvic radiation may be a viable salvage treatment option.
Area of Science:
- Oncology
- Radiation Oncology
- Urology
Background:
- Brachytherapy, specifically Iodine-125 (125I) implantation, is a common treatment for low-risk prostate adenocarcinoma.
- Biochemical failure, indicated by rising prostate-specific antigen (PSA) levels, can occur even after successful brachytherapy.
- Prostate-specific antigen (PSA) failure is generally uncommon in appropriately selected brachytherapy patients.
Observation:
- This case report details a patient with low-risk prostate adenocarcinoma who experienced biochemical failure following 125I brachytherapy.
- The patient presented with rising PSA levels post-treatment, indicating treatment failure.
Findings:
- Salvage treatment involving neoadjuvant/adjuvant hormonal therapy combined with pelvic external-beam radiation therapy was administered.
- At a 2-year follow-up, the patient is reported to be doing well, suggesting potential efficacy of the salvage approach.
Implications:
- This case suggests that a combination of hormonal therapy and pelvic radiation may be a reasonable salvage strategy for select patients with biochemical failure after brachytherapy.
- Further research and data collection are needed to establish definitive salvage management protocols, as current approaches remain investigational.